Nanobody Market

The global nanobody market is emerging due to the increasing prevalence of chronic diseases, rising demand for precision medicine, and increasing investment in nanobody research and development. Additionally, the growing development of new applications of nanobodies will provide growth opportunities for the market in the future. However, the manufacturing challenges and high production costs might hamper the market's growth in the forecast period.

There has been a significant increase in the prevalence of chronic diseases such as cancer, autoimmune diseases, neurological disorders, blood disorders, and others which has led to an increased demand for targeted therapies. Nanobodies have shown promise in treating these conditions due to their ability to target specific cells and tissues. Nanobodies are small antibody fragments that have several advantages over traditional antibodies, such as greater stability, better tissue penetration, and reduced immunogenicity. The rising prevalence of autoimmune diseases and other chronic disorders demands the discovery of newer and more effective nanobody-based drugs for their treatment. For instance, in February 2019, the United States Food and Drug Administration (FDA) approved Cablivi (caplacizumab-yhdp), the first nanobody-based medicine of Sanofi S.A. (France), for adults with acquired thrombotic thrombocytopenic purpura (aTTP). The growing incidence of autoimmune diseases such as rheumatoid arthritis and other chronic diseases is anticipated to fuel the market growth during the assessment period. For instance, as per the National Stem Cell Foundation (US), approximately 4% of the world's population is affected by one of more than 80 different autoimmune diseases, the most prevalent of which are type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. Similarly, according to the International Agency for Research on Cancer (France), approximately 19.3 million new cancer cases worldwide in 2020, with lung, breast, colorectal, prostate, and stomach cancers being the most common.

Additionally, according to the World Health Organization (WHO), chronic diseases such as cancer, cardiovascular disease, and diabetes are responsible for 74% of all deaths globally. The incidence and prevalence of these diseases are expected to continue to rise, driven by factors such as aging populations, changing lifestyles, and increasing urbanization. In response to this growing burden, there is a need for new and innovative therapies that can address these diseases effectively. Nanobodies are a promising avenue for drug development in this regard, as they offer several advantages over traditional antibodies. Nanobodies have the ability to target specific disease-causing molecules, such as tumor markers or inflammatory cytokines. This specificity makes them attractive as potential therapeutic agents for a range of chronic diseases. For example, nanobodies have shown promise in preclinical and clinical trials for the treatment of cancer, rheumatoid arthritis, and multiple sclerosis. For instance, M 6495 of Ablynx (Belgium) and Merck KGaA (Germany) initaited phase I trials for osteoarthritis in Denmark. Hence, the increasing prevalence of chronic diseases, combined with the unique advantages of nanobodies drives market growth.

The increase in the development of new applications of nanobodies represents a significant opportunity for the pharmaceutical & biotechnology industry. Nanobodies are a unique class of antibodies that offer a number of advantages over traditional monoclonal antibodies, including their small size, stability, and ability to target difficult-to-reach epitopes. As a result, they are being increasingly explored for a wide range of applications beyond their initial use in research and diagnostics. One of the most promising new applications of nanobodies is in the field of therapeutics. Nanobodies have already shown great potential in treating a variety of diseases, including cancer, infectious diseases, and inflammatory disorders. Additionally, they have been used to develop new imaging agents and diagnostic tools, as well as for targeted drug delivery. Moreover, another area where nanobodies are being explored is the development of new biologics, due to their small size and unique binding properties suited for the development of new therapeutics with improved efficiency and safety. For instance, in November 2022, MassBiologics (US) developed the VHH-IgA biologic, which is a fusion of an antigen-binding fragment of the COVID spike protein and a human IgA antibody for treating SARS-CoV-2 infection. As a result, the nanobody market is expected to see significant expansion due to the growing development of new applications of nanobodies for the diagnosis and treatment of several chronic diseases.

The manufacturing process for nanobodies can be complex and challenging, which is a significant restraint on the development of these therapies. One of the primary challenges is the need for a larger and more complicated infrastructure for the production of nanobodies. This is because nanobodies are derived from camelids, such as llamas or camels, and are typically produced in specialized cells located in the animal’s bone marrow. To produce nanobodies, researchers first need to immunize the animal with the target antigen. This process triggers the production of specialized immune cells called B-cells, which produce nanobodies against the antigen. Once the B-cells have been isolated from the animal, researchers can extract the nanobodies and clone them to produce a large enough quantity for therapeutic use. However, the process of extracting and cloning nanobodies can be complex and time-consuming. In addition, the specialized cells used to produce nanobodies are typically housed in a larger and more complicated system than those used for traditional cell lines, which can add to the manufacturing costs and logistical challenges. Moreover, another challenge associated with the manufacturing process for nanobodies is the need for specific purification methods this requires specialized purification techniques, which can add to the overall cost and complexity of the manufacturing process. Thus, the complex manufacturing process and high production costs for nanobodies are anticipated to restrain the growth of the market.